BIVDA Press Releases

May 13, 2021
IPSWICH, MA (May 10th, 2021) — New England Biolabs, Inc. (NEB®), a leading supplier of life science reagents, today announces that it has entered into an agreement to acquire Fluorogenics Limited (FGL), a lyophilization R&D service company based in the UK. Under the terms of the agreement, FGL will become a wholly-owned subsidiary of NEB. With the point-of-care market becoming more focused on the development of robust, accurate and cost-effective diagnostic tests for use outsi...
Read More
May 11, 2021
BIVDA Chief Executive Doris-Ann Williams and Chief Operating Officer Helen Dent have commented on the publication of the Health and Care Bill in today’s Queen’s Speech.  Commenting on plans to promote integrated care in the health service, Doris-Ann said; “The new White Paper offers an opportunity to promote joint working and collaboration in the NHS across different teams, department and disciplines. As part of these reforms, we want to see greater use of IVDs in pri...
Read More
May 07, 2021
BIVDA commentary on proposed validation of COVID Antigen tests for sale in the private sector7th May 2021 After careful consideration, BIVDA believes that setting up a separate validation process sets both an unwarranted precedent for the industry and undermines the regulatory system. Our position is that changes to the existing regulatory regime could achieve what the validation policy is trying to do, more effectively and without creating a two-layer system – a view in which we are ...
Read More
Apr 26, 2021
FluoretiQ Ltd. today announced the appointment of Mr Kasra Saeb-Parsy Consultant Urologist with Cambridge (UK) University Hospitals NHS Foundation Trust as their Chief Medical Officer. Mr. Saeb-Parsy will oversee and lead all clinical development, regulatory and medical affairs strategies and activities of the Company."I am delighted to welcome Kasra as our Chief Medical Officer at this key stage of our company growth as we approach clinical studies and regulatory approval in the UK and USA...
Read More
Apr 19, 2021
BIVDA welcomes NICE Five Year Plan BIVDA, the trade association for British IVD companies,  has welcomed the publication of NICE’s five year strategy document. The document runs from 2021 to 2026 and is designed to ensure the organisation remains “excellent”, more dynamic and more collaborative in their work. According to NICE,  the plan puts science and evidence at the heart of health and care decision making, while keeping ahead of the challenges of a rapidly c...
Read More
Apr 07, 2021
BIVDA, the trade association for British in-vitro diagnostic companies, has welcomed the launch of the ‘Medicines and Diagnostics Manufacturing Transformation Fund’ which is now open for applications. The new fund of £20 million is dedicated to expanding the manufacturing capacity of the life sciences industry.  The fund is open to manufacturers of human licensed medicines, medical diagnostics and medical devices, and projects must have a minimum total size of 8M, wit...
Read More
Apr 01, 2021
BIVDA launches the Don’t Wait;Act Testing Campaign For Immediate Release  -- BIVDA, the trade association for British in-vitro diagnostic companies, has launched its new Don’t Wait;Act campaign to re-start testing for non-COVID health issues today. Routine care and health screening for diseases such as cancers, heart disease and diabetes have either experienced long pauses or drops in take-ups from members of the public during the COVID-19 pandemic. As a result, t...
Read More
Mar 23, 2021
BIVDA welcomes new Government research strategy BIVDA, the trade association for British in-vitro diagnostic companies, has welcomed the publication of the Government’s new research strategy ‘Saving and improving lives: the future of UK clinical research delivery’. The strategy sets out plans to strengthen the UK’s renowned expertise as a world-leader in designing and delivering medical and scientific research. It is built around 5 key themes:  Clinical research...
Read More
Mar 22, 2021
BIVDA Welcomes new EUCOPE – Charles River Associates report on advanced diagnostics  BIVDA, the UK trade association for in-vitro diagnostic companies, has welcomed the publication of a White Paper on Advanced Diagnostics by EUCOPE and Charles River Associates that puts forward concrete proposals to support understanding of the advanced diagnostics sector, the benefits it brings and related requirements for success . The health benefits of genomics and advanced genomic testing ar...
Read More
Mar 18, 2021
MICROSENSDX RapiPRO™ LAMP for SARS-CoV-2 RECEIVES CE MARK APPROVAL Pioneering British biotech MicrosensDx has announced that its RapiPRO™ LAMP SARS-CoV-2 test has received CE Certification.The business, an established molecular diagnostics innovator with a 20-year history in IVD development, is a recognised expert in Loop-mediated Isothermal Amplification (LAMP) testing, having developed proprietary tuberculosis (TB) diagnostics using the technology.MicrosensDx has revealed robu...
Read More
Page 4 of 11 [4]